BiotechTube
ABCDx

ABCDx

Geneva, Switzerland· Est.
abcdx.es
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

ABCDx is a private, pre-revenue diagnostics company developing a novel platform for point-of-care brain injury assessment. Founded in 2015 and based in Geneva, Switzerland, with a significant operational presence in Barcelona, Spain, the company's core technology revolves around blood-based biomarkers and a proprietary software platform to differentiate stroke types and detect mild TBI. Led by scientific founders who are key opinion leaders in brain biomarkers, ABCDx is building a robust intellectual property portfolio with granted patents in key markets including the U.S., China, and Europe, positioning itself to address critical unmet needs in neuro-emergency diagnostics.

NeurologyStrokeTraumatic Brain Injury

Technology Platform

Proprietary blood-based biomarker panels integrated with a Software as a Medical Device (SaMD) platform for point-of-care diagnosis of brain injuries.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The massive, unmet need for rapid diagnosis in stroke and TBI creates a multi-billion dollar market.
The shift towards decentralized, point-of-care testing and digital health (SaMD) aligns perfectly with ABCDx's platform.
Its robust and expanding IP portfolio in key global markets provides a strong competitive moat and potential for lucrative licensing deals.

Risk Factors

The company faces significant regulatory hurdles in obtaining FDA/CE Mark clearance for its novel diagnostic devices.
Successful clinical validation in large, diverse populations is required to prove utility.
Post-approval, achieving widespread clinical adoption and reimbursement from healthcare payers presents a major commercialization challenge.

Competitive Landscape

ABCDx competes in the neuro-diagnostic space with large IVD companies (e.g., Roche, Abbott) investing in stroke biomarkers, as well as specialized startups (e.g., BrainBox, DiamiR) and academic spin-offs. Its differentiation lies in its integrated SaMD platform, a focus on point-of-care applications, and the deep, direct KOL involvement of its founders in biomarker discovery.

More companies in Diagnostics & Precision Medicine →More companies in Switzerland →